Please login to the form below

Not currently logged in
Email:
Password:

Novartis' Entresto gets EU green light

Winsapproval for symptomatic chronic heart failure with reduced ejection fraction

Novartis building

Novartis much-anticipated new heart failure drug Entresto has been approved in the EU, providing a new treatment option for millions of patients.

Entresto (sacubitril and valsartan) has been cleared for the treatment of adult patients with symptomatic chronic heart failure with reduced ejection fraction (HFrEF) and is dosed as a twice-daily tablet.

Around 3.5 million patients are diagnosed with HF every year in Europe, and there are around 15 million people living with the condition, with 50% of these dying within five years of diagnosis. Around half of all HF diagnoses involve patients with reduced ejection fraction.

Entresto's entry into the market has been keenly anticipated as treatment for chronic HF has not seen any major advances for many years. The approval is backed by data from the PARADIGM-HF trial, which showed the drug cut cardiovascular deaths by 20% versus standard therapy based on the ACE inhibitor enalapril, while also reducing hospitalisations by 21% and all-cause mortality by 16%. 

Meanwhile, Novartis gained a big boost for the new product after the Institute for Clinical and Economic Review (ICER) concluded it was both clinically effective and appropriately priced. Given, the huge eligible patient population, some analysts predict Entresto could eventually become a $5bn product

The approval by the European Commission comes four months after Entresto was given the go-ahead in the US, its first market. It has also been registered in Switzerland and Canada, and made around $16m in sales in the third quarter.

Sales to date have remained modest mainly because two-thirds of patients eligible for treatment with the drug in the US are under Medicare, and it has taken time for Entresto to be added to Medicare Part D formularies. Novartis has said it expects this situation to resolve within the next six months or so and that US sales will accelerate as EU countries come on-line.

The Entresto news comes hard on the heels of another important approval for Novartis - EU approval of two new indications for anti-inflammatory drug Cosentyx (secukinumab), another drug with multibillion dollar sales potential.

Article by
Phil Taylor

24th November 2015

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Say Communications

Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...

Latest intelligence

EU
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...
Nudge-nudge, think-think
Chris Ross examines the personal complexities of human behaviour – and explains why fun, emotion and peer endorsement could be key to designing effective behavioural change programmes...
Peoples Award
Quality in Care Diabetes 2018: the best in innovative diabetes care
Awards highlight new evidence-based approaches to improving care...

Infographics